Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
9601065 | Clinical Oncology | 2005 | 7 Pages |
Abstract
The treatment of PCNSL is associated with significant early and late toxicity. Further attempts to improve treatment should address mechanisms to reduce this toxicity. In particular, the benefit of radiotherapy in patients who achieve complete remission with HDMTX will remain uncertain until it is addressed in a multicentre, randomised trial.
Related Topics
Health Sciences
Medicine and Dentistry
Oncology
Authors
D.J. Hodson, K.M. Bowles, L.J. Cooke, S.L. Kläger, G.A. Powell, R.J. Laing, J.W. Grant, M.V. Williams, N.G. Burnet, R.E. Marcus,